- Home
- QSI vs EYPT Comparison
QSI vs EYPT Comparison
Compare QSI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QSI
- EYPT
- Stock Information
- Founded
- QSI 2013
- EYPT 1987
- Country
- QSI United States
- EYPT United States
- Employees
- QSI N/A
- EYPT N/A
- Industry
- QSI Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- QSI Health Care
- EYPT Industrials
- Exchange
- QSI Nasdaq
- EYPT Nasdaq
- Market Cap
- QSI 219.8M
- EYPT 579.4M
- IPO Year
- QSI N/A
- EYPT 2005
- Fundamental
- Price
- QSI $1.90
- EYPT $9.55
- Analyst Decision
- QSI Strong Buy
- EYPT Strong Buy
- Analyst Count
- QSI 3
- EYPT 8
- Target Price
- QSI $2.38
- EYPT $24.75
- AVG Volume (30 Days)
- QSI 7.9M
- EYPT 841.7K
- Earning Date
- QSI 08-06-2025
- EYPT 08-06-2025
- Dividend Yield
- QSI N/A
- EYPT N/A
- EPS Growth
- QSI N/A
- EYPT N/A
- EPS
- QSI N/A
- EYPT N/A
- Revenue
- QSI $3,443,000.00
- EYPT $56,042,000.00
- Revenue This Year
- QSI $77.57
- EYPT N/A
- Revenue Next Year
- QSI $251.34
- EYPT N/A
- P/E Ratio
- QSI N/A
- EYPT N/A
- Revenue Growth
- QSI 167.94
- EYPT 12.04
- 52 Week Low
- QSI $0.61
- EYPT $3.91
- 52 Week High
- QSI $5.77
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- QSI 56.65
- EYPT 61.03
- Support Level
- QSI $1.87
- EYPT $7.94
- Resistance Level
- QSI $2.14
- EYPT $10.77
- Average True Range (ATR)
- QSI 0.14
- EYPT 0.76
- MACD
- QSI 0.01
- EYPT -0.01
- Stochastic Oscillator
- QSI 59.32
- EYPT 56.89
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.